Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,566

Document Document Title
WO/2020/187721A1
A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.  
WO/2020/181687A1
A preparation method for and an intermediate of a drug-linker for an antibody drug conjugate MC-MMAF. The reaction activity of the N-terminus is improved, so that the occurrence of a racemic reaction is effectively controlled. The toxin ...  
WO/2020/181688A1
The present invention sets forth a preparation method for a drug-linker MC-MMAF used as an antibody-drug conjugate, and an intermediate thereof. The preparation method of the present invention improves the reactivity of an N-terminal, th...  
WO/2020/178841A1
Self-assembled structures formed of a plurality of cyclic peptides which are in association with metal ions is provided. The cyclic peptides are each of from 2 to 6 amino acid residues, and two or more of the amino acid residues are each...  
WO/2020/172749A1
Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as metho...  
WO/2020/175570A1
A brain function regulator that comprises a peptide containing an amino acid sequence represented by Glu-Hyp-Gly, a salt thereof or a chemical modification of the same.  
WO/2020/172072A1
This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for treating various diseases or disorders (e.g., IgE-mediated disorders). The methods include administering to the subject an effective amount of a c...  
WO/2020/172197A1
The present disclosure provides labeling reagents for labeling substrates such as nucleotides, proteins, antibodies, lipids, and cells. The labeling reagents provided herein may comprise fluorescent labels and semi-rigid linkers. Methods...  
WO/2020/170185A1
The present invention provides substantially pure Lanreotide or its salt and preparation thereof. In another aspect present invention provides a method of preparing Lanreotide dmg product which involves measuring D-Allo-Threonine Lanreot...  
WO/2020/166600A1
A compound represented by formula (1) or a salt thereof. [In formula (1), b is an integer of 1-5, X represents -NH- or -CO-, Z represents a group represented by, for example, formula (Z-1), R1 represents a hydrogen atom or (AB)m, AB repr...  
WO/2020/166592A1
A compound or represented by formula (1) or a salt thereof (in the formula, R1 represents a hydrogen atom or a sulfonyl group, and Z represents a group represented by formula (Z-1), etc.).  
WO/2020/132658A3
Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.  
WO/2020/161683A1
The invention relates to a compound of formula (I) R1 - Wm-Xn-AAi - AA2-AA3-AA4-AA5-AA6- Yp-Zq-Ra, a stereoisomer and/or cosmetically acceptable salt thereof wherein: AA1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA2 is Val, Ile, Leu ...  
WO/2020/159441A1
The present disclosure relates generally to compounds or a salt, solvate, stereoisomer and prodrug thereof for forming synthetic membrane channels. The present disclosure also relates to methods of synthesizing the compounds, methods of ...  
WO/2020/154679A1
The present invention relates to novel small molecules Formula I and pharmaceutically acceptable salts thereof as well as the preparation and the use thereof to inhibit FGFl3-lb.  
WO/2020/117099A4
The invention relates to the field of biologically active compounds and concerns novel dipeptides of the formula R1-C(O)-X-AA1-Y-AA2-R2, where X=L or D configuration, Y=L or D configuration; АA1 is Trp or Gly; АA2 is Leu or Gly; and...  
WO/2020/145584A1
The present invention relates to a novel serine derivative compound having improved blood-brain barrier (BBB) permeability, and a use of same, and more specifically, to a novel serine derivative compound having further improved BBB perme...  
WO/2020/142825A1
It is provided an achiral, non-nucleosidic backbone for phosphoramidites that can be inserted with high yields in nucleic acid strands and sequence-controlled oligo(phosphodiester)s through solid phase synthesis (SPS) using a DNA synthes...  
WO/2020/132597A8
The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS...  
WO/2020/144294A1
The present application is directed to a sensor for detection and/or concentration determination of metal ions in a fluid comprising a complexing agent suitable for binding the metal ions to be detected, detection means and a linker moie...  
WO/2020/146878A1
The application relates to salts of a compound of rapastinel, pharmaceutical compositions thereof, and uses of the salt forms for the treatment of cognitive and neurological diseases and disorders: (Formula I).  
WO/2020/141478A1
The present invention provides novel thiazolyl peptide compounds and their pharmaceutically acceptable salts either alone or in combinations with Rifampicin, Amikacin and Clarithromycin against infections caused by Nontuberculous mycobac...  
WO/2020/134727A1
The present invention discloses a tetrapeptide compound, a preparation method and a use thereof. The tetrapeptide compound of the present invention is TP represented by formula 1, the preparation method thereof is firstly preparing an in...  
WO/2020/136312A1
The invention relates to a method for synthesising peptides or proteins by successively elongating the second end of a peptide chain, the carboxylic acid function (C-terminal) or the amine function Na of which is attached to an anchoring...  
WO/2020/132597A1
The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS...  
WO/2020/132658A2
Provided herein are compounds, compositions, and methods for the treatment of diseases and disorders associated with cancer, including tubulysins and protein (e.g., antibody) drug conjugates thereof.  
WO/2020/125045A1
Provided is a method for synthesizing romidepsin, comprising the following steps: 1) coupling a solid phase synthetic resin with Fmoc-L-Val-OH under the action of an activator to obtain an intermediate I; 2) according to an Fmoc solid ph...  
WO/2020/131282A1
Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.  
WO/2020/131283A1
Disclosed are analogs of elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.  
WO/2019/183265A9
The presently disclosed subject matter relates to peptides and flavor compositions that include at least one, two, three, four, five or more peptide compounds, and screening methods for identifying the same. The flavor compositions can b...  
WO/2020/119192A1
A method for the dual-target construction of PROTAC and a specific construction method and use of dual-target PROTAC constructed using the method. The concept of dual-target design of PROTAC is proposed for the first time. That is, speci...  
WO/2020/123964A1
Antigenic compositions comprising one or more labyrinthin-derived peptides are described herein. In some embodiment, each peptide of the antigenic composition comprises a T-cell epitope and/or a B-cell epitope. In other aspects, the pres...  
WO/2020/121304A1
Provided herein is a class of anti-cancer conjugates designed to cross the blood-brain barrier (BBB) and thereby deliver a methylation agent into cancerous tumor cells, wherein the conjugate comprises a BBB-shuttle moiety that allows the...  
WO/2020/118035A1
The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods compri...  
WO/2020/117990A1
The present invention relates to methods of treating opioid dependence, enhancing the treatment of opioid dependence, treating opioid withdrawal, or alleviating one or more opioid withdrawal symptoms in a subject, preventing or reducing ...  
WO/2020/118188A1
The disclosure relates to compositions that promote liver health. The disclosure also relates to compositions that prevent, mitigate, relieve or reduce the symptoms of hangover.  
WO/2020/117099A1
The invention relates to the field of biologically active compounds and concerns novel dipeptides of the formula R1-C(O)-X-AA1-Y-AA2-R2, where X=L or D configuration, Y=L or D configuration; АA1 is Trp or Gly; АA2 is Leu or Gly; and...  
WO/2020/111217A1
The purpose of the present invention is to provide a technique for reducing the bitterness of Hyp-Gly in a liquid composition for oral use that contains a specific amount of Hyp-Gly. The present invention pertains to a liquid composition...  
WO/2020/106780A1
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...  
WO/2020/101318A1
The present invention provides a method for producing an N-acetyl dipeptide and an N-acetyl amino acid, comprising the step of reacting an amino acid with acetic anhydride or acetyl chloride to form an N-acetyl dipeptide and an N-acetyl ...  
WO/2020/093187A1
Disclosed is an application of an aspartic acid derivative having a structure represented by formula (I), or a racemate, stereoisomer, geometric isomer, tautomer, solvate or feed-acceptable salt thereof, in preparing an animal feed addit...  
WO/2018/093449A9
A self-assembling peptide is provided that is enzymatically oxidized to form a polymeric pigment. The monomeric peptide has three amino acids (tyrosine (Y), one phenylalanine (F), and one aspartic acid (D) or one lysine (K)) and, followi...  
WO/2020/096240A1
The present invention relates to: a method for stabilizing and preventing oxidation of glutathione which is an antioxidant; an aptamer having such activity; and applications of the aptamer to various fields, such as medicine, cosmetics, ...  
WO/2020/093142A1
The present disclosure concerns peptide compounds of formula (I) or (II) and combinations thereof that can be administered orally for promoting endogenous steroid, and particularly testosterone, production: A-Xaa1Xaa2-Xaa3-Xaa4-Xaa5-Xaa6...  
WO/2020/097531A1
Disclosed are compounds, compositions, and methods involving theranostic capture agent for a target where the capture agent is (a) a precursor that can be loaded with a detectable moiety, a therapeutic moiety, or both, (b) loaded with a ...  
WO/2020/096020A1
The purpose of the present invention is to provide a method for producing a peptide that interacts with a lipid bilayer, and a lipid-bilayer-penetrating peptide obtained through the method. Provided is a lipid-bilayer-penetrating peptide...  
WO/2020/092705A1
Novel self-assembling pentapeptides and peptides containing such self-assembling pentapeptides, self-assembled hydrogels, and methods of making and using the same are described. These pentapeptides, and peptides containing such pentapept...  
WO/2020/092139A1
Provided herein are novel compounds of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical compositions comprising the same. Also provided are methods of preparing the compounds of Formula I, or pharmaceutically ac...  
WO/2020/091513A1
The present invention relates to a pharmaceutical composition comprising a peptide inhibiting the toll-like receptor (TLR) signaling pathway as an active ingredient for preventing or treating lupus. The pharmaceutical composition accordi...  
WO/2019/160793A3
A synthetic sweat composition, sweat odor kit, and method of use are provided. The synthetic sweat composition comprises an odor-precursor of eccrine sweat and an odor pre-cursor of apocrine sweat. The method comprises combining a synthe...  

Matches 1 - 50 out of 17,566